1. Microbiol Spectr. 2022 Oct 26;10(5):e0292722. doi: 10.1128/spectrum.02927-22. 
Epub 2022 Aug 31.

Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from 
ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies).

Hernández-García M(1)(2), García-Castillo M(1), Bou G(2)(3), Cercenado E(4), 
Delgado-Valverde M(2)(5), Oliver A(2)(6), Pitart C(7), Rodríguez-Lozano J(8), 
Tormo N(9), Melo-Cristino J(10), Pinto MF(11), Gonçalves E(12), Alves V(13), 
Vieira AR(14), Ramalheira E(15), Sancho L(16), Diogo J(17), Ferreira R(18), Cruz 
H(19), Chaves C(20), Duarte J(21), Pássaro L(21), Díaz-Regañón J(22), Cantón 
R(1)(2).

Author information:
(1)Servicio de Microbiología, Hospital Universitario Ramón y 
Cajalgrid.411347.4-IRYCIS, Madrid, Spain.
(2)CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos 
III, Madrid, Spain.
(3)Servicio de Microbiología, Hospital Universitario A Coruña, A Coruña, Spain.
(4)Servicio de Microbiología Clínica y Enfermedades Infecciosas, Hospital 
General Universitario Gregorio Marañóngrid.410526.4, Madrid, Spain.
(5)Unidad Clínica de Enfermedades Infecciosas y Microbiología, Instituto de 
Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen 
Macarena/CSIC/Universidad de Sevilla, Sevilla, Spain.
(6)Servicio de Microbiología, Hospital Universitario Son Espasesgrid.411164.7, 
Palma de Mallorca, Spain.
(7)Servicio de Microbiología, Hospital Clínic i Provincial, Barcelona, Spain.
(8)Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla, 
Santander, Spain.
(9)Servicio de Microbiología, Consorcio Hospital General Universitario de 
Valencia, Valencia, Spain.
(10)Laboratório de Microbiologia, Centro Hospitalar Universitário Lisboa Norte, 
Lisboa, Portugal.
(11)Laboratório de Microbiologia, Serviço de Patologia Clínica, Centro 
Hospitalar Universitário Lisboa Central, Lisboa, Portugal.
(12)Laboratório de Microbiologia Clínica, Centro Hospitalar de Lisboa Ocidental, 
Lisboa, Portugal.
(13)Laboratório de Microbiologia, Unidade Local de Saúde de Matosinhos, 
Matosinhos, Portugal.
(14)Serviço de Patologia Clínica, Centro Hospitalar Universitário São João, 
Porto, Portugal.
(15)Serviço Patologia Clínica, Hospital Infante Dom Pedro, Aveiro, Portugal.
(16)Serviço de Patologia Clínica, Hospital Professor Fernando da Fonseca, 
Amadora, Portugal.
(17)Serviço de Microbiologia, Hospital Garcia de Orta, Almada, Portugal.
(18)Serviço de Patologia Clínica-Microbiologia, CHUA-Unidade de Portimão, 
Portimão, Portugal.
(19)Serviço de Microbiologia, Centro Hospitalar Universitário do Porto, Porto, 
Portugal.
(20)Serviço de Microbiologia, Centro Hospitalar Universitário de Coimbra, 
Coimbra, Portugal.
(21)MSD Portugal, Paço de Arcos, Portugal.
(22)Departamento Médico, MSD España, Madrid, Spain.

Imipenem-relebactam is a novel β-lactam-β-lactamase inhibitor combination. We 
evaluated the in vitro activity of imipenem-relebactam and comparators against 
Enterobacterales clinical isolates recovered in 8 Spanish and 11 Portuguese 
intensive care units (ICUs) (SUPERIOR, 2016-2017; STEP, 2017-2018). Overall, 747 
Enterobacterales isolates (378 Escherichia coli, 252 Klebsiella spp., 64 
Enterobacter spp., and 53 other species) were prospectively collected from ICU 
patients with complicated intraabdominal (cIAI), complicated urinary tract 
(cUTI), and lower respiratory tract (LRTI) infections. MICs were determined 
(ISO-broth microdilution), and whole-genome sequencing (WGS) was performed in a 
subset of isolates displaying susceptible and resistant imipenem-relebactam 
MICs. Imipenem-relebactam (98.7% susceptible) showed similar activity to 
ceftazidime-avibactam (99.5% susceptible) and higher than ceftolozane-tazobactam 
(86.9% susceptible). Imipenem-relebactam was inactive against 1.3% (10/747) 
isolates, all of them due to carbapenemase production (9 K. pneumoniae and 1 E. 
cloacae). Imipenem-relebactam was active against 100% of extended-spectrum 
β-lactamase (ESBL)-E. coli and ESBL-Klebsiella spp. isolates and 80.4% of 
carbapenemase-Klebsiella spp. producers. Carbapenemase genes were confirmed by 
WGS in 41 Klebsiella spp.: OXA-48 (20/41), KPC-3 (14/41), OXA-181 (4/41), NDM-1 
(1/41), OXA-48 + VIM-2 (1/41), and KPC-3 + VIM-2 (1/41). In Klebsiella spp. 
isolates, relebactam restored imipenem susceptibility in all KPC-3 producers, 
and resistant isolates (7/41) were mostly OXA-48 + CTX-M-15-K. pneumoniae 
high-risk clones (7/9). Intercountry differences were detected as follows: 
OXA-48 (17/21) was dominant in Spain, unlike KPC-3 (14/15) in Portugal. 
Imipenem-relebactam was 100% active against CTX-M-15-ST131-H30Rx-E. coli 
high-risk clone, predominant in both countries. Our results depict the potential 
role of imipenem-relebactam in ICU patients with cIAIs, cUTIs, and LRTIs due to 
wild-type ESBL- and carbapenemase-producing Enterobacterales, particularly KPC 
producers. IMPORTANCE We comparatively evaluate the in vitro activity of a drug 
combination consisting of a carbapenem (imipenem) and a novel inhibitor of 
beta-lactamases (relebactam), a mechanism that destroys beta-lactam antibiotics. 
We assess the activity against a collection of Enterobacterales clinical 
isolates recovered from difficult-to-treat infections in patients admitted to 
different intensive care units in Portugal and Spain. Imipenem-relebactam shows 
excellent activity in avoiding common resistance mechanisms in this setting, 
such as extended-spectrum beta-lactamases and carbapenemases widely distributed, 
including KPCs. We show few resistant isolates (<2%). Molecular characterization 
by whole-genome sequencing shows that most of the resistant isolates produced 
specific carbapenemase, such as OXA-48 or metalo-betalactamases. Our study 
updates the activity of imipenem-relebactam in light of current epidemiology in 
a hospital setting in which the use of this combination is needed due to the 
presence of infections due to multidrug-resistant isolates.

DOI: 10.1128/spectrum.02927-22
PMCID: PMC9602286
PMID: 36043877 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare a conflict of interest. R.C. 
and A.O. have participated in educational programmes and research grants 
organized by MSD, Pfizer and Shionogi. J.M.-C., G.B. and E.C. have participated 
in educational programmes organized by MSD and Pfizer. M.F.P. had a travel grant 
for ECCMID-2019 from MSD Portugal. J.D. and L.P. are MSD Portugal employees 
and/or may hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA. J.D.-R. 
is employee of MSD Spain. All other authors declare no competing interests.